Japan’s Daiichi Sankyo has presented impressive results on patritumab deruxtecan (HER3-DXd), a specifically engineered potential first-in-class HER3 directed an 11 September 2023
Following its first Chinese approval earlier this year, a next generation BTK blocker, Calquence (acalabrutinib), has picked up another nod in the country. 4 September 2023
Japanese drugmaker Kyowa Kirin has received approval in its home country for a higher-dose formulation of its oral calcimimetics agent Orkedia (evocalcet). 30 August 2023
A new discovery and development collaboration has been agreed between Boston, USA-based Verastem Oncology and Shanghai's GenFleet Therapeutics. 29 August 2023
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.